ROCKWELL MEDICAL, INC.RMTIEarnings & Financial Report
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
RMTI Q1 FY2026 Key Financial Metrics
Revenue
$17.3M
Gross Profit
$2.9M
Operating Profit
N/A
Net Profit
$-1.6M
Gross Margin
16.8%
Operating Margin
N/A
Net Margin
-9.2%
YoY Growth
-8.5%
EPS
$-0.04
ROCKWELL MEDICAL, INC. Q1 FY2026 Financial Summary
ROCKWELL MEDICAL, INC. reported revenue of $17.3M (down 8.5% YoY) for Q1 FY2026, with a net profit of $-1.6M (-9.2% margin). Cost of goods sold was $14.4M.
Key Financial Metrics
| Total Revenue | $17.3M |
|---|---|
| Net Profit | $-1.6M |
| Gross Margin | 16.8% |
| Operating Margin | N/A |
| Report Period | Q1 FY2026 |
ROCKWELL MEDICAL, INC. Annual Revenue by Year
ROCKWELL MEDICAL, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $69.3M).
ROCKWELL MEDICAL, INC. Quarterly Revenue & Net Profit History
ROCKWELL MEDICAL, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $17.3M | -8.5% | $-1.6M | -9.2% |
| Q4 FY2025 | $18.3M | -25.6% | $-554.0K | -3.0% |
| Q3 FY2025 | $15.9M | -43.8% | $-1.8M | -11.0% |
| Q2 FY2025 | $16.1M | -37.8% | $-1.5M | -9.3% |
| Q1 FY2025 | $18.9M | -16.6% | $-1.5M | -8.0% |
| Q4 FY2024 | $24.7M | +11.6% | $-756.0K | -3.1% |
| Q3 FY2024 | $28.3M | +19.1% | $1.7M | 5.9% |
| Q2 FY2024 | $25.8M | +42.9% | $343.0K | 1.3% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.8M | $28.3M | $24.7M | $18.9M | $16.1M | $15.9M | $18.3M | $17.3M |
| YoY Growth | 42.9% | 19.1% | 11.6% | -16.6% | -37.8% | -43.8% | -25.6% | -8.5% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $53.0M | $57.1M | $59.2M | $54.0M | $52.6M | $57.5M | $57.1M | $57.4M |
| Liabilities | $29.5M | $27.9M | $26.6M | $22.4M | $22.2M | $20.5M | $20.2M | $21.6M |
| Equity | $23.5M | $29.1M | $32.6M | $31.5M | $30.4M | $37.0M | $37.0M | $35.9M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $1.4M | $4.3M | $865000 | $-3.5M | $1.8M | $-1.3M | $2.3M |